India Pharmaceutical Market: domestic size, exports and outlook 2026–2032

India’s pharmaceutical industry is the world’s largest supplier of generic medicines by volume and a fast-growing domestic market in its own right. Published estimates for the 2025 domestic market range from USD 28.0 bn to USD 60.0 bn; our central estimate is USD 28.0 bn, growing at about 8% to USD 48.0 bn by 2032. Exports are of a similar order of magnitude and growing, led by the US, Africa, the UK and increasingly the GCC.

The domestic market is a branded-generics market: thousands of brands of the same molecules, sold through a dense distribution chain, with price control on NLEM molecules (DPCO) and the Jan Aushadhi scheme pushing unbranded generics. For hospital buyers this means large price dispersion for the same molecule — and large savings from tendering by molecule and class rather than by brand.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 28.0 bn–USD 60.0 bn; differences are mostly scope.

Included: domestic formulations (prescription and OTC), biologics and vaccines; exports reported as context. Excluded: APIs (reported as context), devices, nutrition. Regulation: CDSCO, NPPA (pricing), state FDAs; Schedule M (revised GMP, 2024–25).

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• India ranks 3rd globally by pharma volume and 11th by value; ~3,000 companies and ~10,500 manufacturing units; ~500 API makers (~8% of global API industry) (PIB)
• India supplies ~20% of global generic medicines; ~60,000 generic brands across 60 therapeutic categories (PIB)
• Exports USD 30.47 bn in FY2024-25 (16x the USD 1.9 bn of 2000-01), to 191 countries, ~50% to highly regulated markets (PIB)
• Jan Aushadhi: 18,646+ kendras (Feb 2026), 2,110 medicines + 315 devices; sales Rs 2,022.47 crore FY25 (citizen savings ~Rs 8,000 crore); Rs 1,409.32 crore Apr-Nov FY26 (PIB)
• Pharma PLI (since 2021): Rs 40,890 crore investment; sales Rs 3,16,797 crore incl. Rs 2,03,730 crore exports; ~97,000 jobs (to Sep 2025) (PIB)
• Bulk drug PLI: 55,100 MT/yr capacity for 26 critical APIs/KSMs; sales Rs 2,313 crore; import avoidance Rs 3,591 crore (PIB)
• GCC = 5.58% of Indian pharma exports; WANA exports USD 1,749.68 mn in FY25 vs USD 1,320.44 mn in FY21 (Medical Dialogues / Pharmexcil)
• US takes 34% and Europe 19% of India's pharma exports; >60% go to highly regulated markets (Pharmexcil, Apr 2026) (Chemindigest)
• Domestic IPM 2025: Rs 2,40,672 crore (+8.1%); 2026 forecast +7.8-8.1%; Augmentin #1 and Glycomet GP #2 on MAT basis; Mounjaro #1 in Dec 2025 (Pharmarack via Tribune)

India

Chronic therapies (cardiac, diabetes, respiratory, CNS) are the growth engine; hospital channel is consolidating with chains; trade generics and e-pharmacy are reshaping retail. Biosimilars (Biocon, Dr Reddy’s, Intas, Zydus, Lupin) and complex generics are the export upgrade.

GCC link

Indian manufacturers supply a large and rising share of generics and biosimilars to Saudi Arabia, the UAE and the wider GCC; the gates are SFDA/MOHAP registration, GMP inspection, serialisation (RSD, Tatmeen) and a local agent. Localisation incentives in Saudi Arabia and the UAE are pulling Indian firms into JVs and local plants.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Hospital leaders (India): molecule- and class-level tenders, NLEM-aware pricing and a validated savings tracker typically take 8–12% off drug spend — see class-level lots.
• Manufacturers: GCC registration and serialisation readiness open the highest-margin export markets within reach; our Network carries GCC hospital demand.
• Investors: biosimilars, complex generics, CDMO and GCC-facing JVs.

1. PIB, Government of India, Pharma sector backgrounder (March 2026) — static.pib.gov.in
2. Chemindigest, India Records 5.6 Percent Growth in Pharmaceutical Exports in FY26 — chemindigest.com
3. News Arena India, Indian pharma sector will grow to $130 bn by 2030 — newsarenaindia.com
4. The Tribune / ANI (Pharmarack), Indian pharma market reached Rs 2.40 lakh crore with 8.1% growth in 2025 — tribuneindia.com
5. BioSpectrum India, Sun Pharma continues to retain No 1 position in IPM for November: Pharmarack — biospectrumindia.com
6. Medical Dialogues, Indian pharma faces Rs 5,000 crore export risk as Middle East conflict drives freight charges up — medicaldialogues.in
7. GeneOnline, India's $58B pharma market eyes $450B by 2047 — geneonline.com
8. India MedToday, Pharmexcil draws robust growth roadmap for India's generic pharmaceutical exports — indiamedtoday.com
9. IANS, India's pharma exports surpass $30 billion in FY25, US top market — ianslive.in
10. Pharmexcil / Government of India (PIB) (2026-03) — USD 60 bn (domestic pharma industry) (2025) to USD 130 bn (2030), CAGR —; scope: Industry size incl. domestic + exports; 3rd by volume, 11th by value globally; sector turnover Rs 4.72 lakh crore FY25 — source
11. Pharmarack (Indian Pharma Industry Performance report, via Tribune/ANI) (2026-01) — Rs 2,40,672 crore (~USD 28 bn) domestic IPM, CY2025 (2025) to +7.8% to +8.1% growth (2026), CAGR 8.1% value growth in 2025; scope: Domestic Indian Pharmaceutical Market (IPM) retail audit; growth mix to Nov-25: price 5.4%, new products 2.1%, volume 0.5% — source
12. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
13. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.